Can REGENXBIO Turn Retina into Anti-VEGF Factory?

Stephen Yoo, MD, chief medical officer of REGENXBIO, which utilizes adeno-associated virus to target disease, laid out the company’s plans to run its RGX-314 gene programs through a Phase I clinical trial of patients with wet age-related macular degeneration. Dr. Yoo says the company is fusing its AAV8 and a gene that encodes for an anti-VEGF fab gene to turn the retina into a “factory of locally produced anti-VEGF fab.” The trial is targeting 18 patients.